Investing.com - Teva Pharma Industries Ltd ADR (NYSE:TEVA) has launched its generic version of Eli Lilly's Axiron topical solution CIII, in the U.S. Axiron is I used to treat adult men with low or no testosterone. The U.S. market is worth approximately $247 million, according to IMS.
Teva's shares were up over 1% following the news.